Outward VC is an early-stage venture capital firm that invests in technology companies with a focus on fintech, healthtech, and consumer internet. The firm provides capital, support, and a network of industry experts to help startups scale and succeed.

Outward VC

Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups that are commercializing university research.  OUP firmly believes that universities provide an unparalleled innovation engine and we have partnered with over 100 of the most entrepreneurial universities and research centers to invest in their startups. Profits are shared with affiliated institutions to further promote the university entrepreneurial ecosystem.

Algorithmia

Voxel8

Spero Therapeutics

Kura Oncology

Sera Prognostics

StreetLight Data

Gevo

Guardant Health

Cyteir Therapeutics

Effector Therapeutics

Beam Therapeutics

Biohaven Pharmaceutical

Bristol-Myers Squibb

Homology Medicines

IonQ

Evolv Technology

Otonomy

Picwell

Clinipace

Precision BioSciences

Osage University Partners (OUP)

What a wonderful event this year! 

A special thanks to the members of the Osage University Partners (OUP) team that helped make this event great: Matthew Cohen and Anurag Agarwal for joining as Advisors, and Matt's opening remarks for the day; and Mitra Miri,  Harim Won, and Kathleen M. for all their work on the Steering Committee.

Keep an eye out for updates for next year's event!

🔔 NEW BLOG POST 🔔 

As a continuation of our "Ask a VC" blog series, Manny Stockman & Anurag Agarwal from Osage University Partners (OUP) answered some frequently asked questions regarding staffing your startup.

🎤 "The idea that technical and business expertise are distinct and separate is not true in my mind. You can find people who are business oriented and highly technical, and it is never too early to hire one person like that." -- Manny

🎤 "Spend a lot of time with the person before you commit. Perform reference checks. Talk to the other founders that have worked with them, people that have reported to them, and individuals they have reported to." -- Anurag

Read the whole blog here: https://lnkd.in/eW7T4kV6

Thank you to our 2024 #Science2Startup fireside chat speaker, David R. Liu, Ph.D., and moderator, Deborah Palestrant, Ph.D., M.B.A., for kicking off this year's event.

During their discussion, Liu spoke about his professional and academic journey, how he began working with #VentureCapital organizations, how he stays committed to science and patient care, and more.

"Problem selection, still very very important. Trust, give anybody who wants to work with you, the opportunity to work with you, if possible. But developing a network of people you trust is really important for translation. And ultimately, for this audience, where I noticed everything was a therapeutics company, keep patient interest upfront. That's such an important guiding star and you can virtually never go wrong if you just keep patient interest upfront, it will help everything. And you also, coincidentally, build the most value if you end up keeping patient interest upfront because all of this is not just a marathon, it's an ultramarathon, so not letting the short-term eccentricities of what an investor did or didn't do, how the value of your stock, if it's publicly traded, is changing or not; don't let that bother you. In the end, if you are actually helping people, if you keep patient interest upfront, you will generate enough value that everybody will be happy that way, and more importantly, in the end, I don't think you're going to care that much about how many digits are in your bank account, which is not even associated with physical money anymore, but I think people will remember you for the impact you had on the lives of patients who maybe didn't have a treatment otherwise."


Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank │ Broad Institute of MIT and Harvard
#biotech #pharma #startup

The 2024 #Science2Startup symposium is tomorrow! After exciting discussions and powerful networking, 8 researchers will present their ideas and interact with leading investors and executives in the Boston #biotech hub.
 
Thank you to our event co-hosts F-Prime Capital, Atlas Venture, 5AM Ventures, RA Capital Management, and MassBio. 

Make sure to follow along for updates!

Thank you to #Science2Startup sponsor Deloitte for hosting this year's academic workshop, “Considerations for setting up your finance organization during company scaling,” presented by B.J. Spence, Deloitte Partner, Accounting & Reporting Advisory (ARA) New England Leader.
 
As a sponsor, you have the unique opportunity to showcase your domain knowledge in the industry with the potential to become the key partner for the startups throughout their company life cycle.
 
To learn more about the event or to get involved, please email us at info@science2startup.com or visit www.science2startup.com.
  
#biotech #pharma #startup

We are delighted to share the #Science2Startup class of 2024. This year’s 8 scientific presenters were selected by an advisory group comprised of experienced biotech investors to present their startup ideas on April 10th at the Broad Institute in Cambridge, Massachusetts.
 
▪️ Rivka Dikstein, Ph.D. - Professor and Dean, Faculty of Biochemistry, Weizmann Institute of Science
▪️ Irina Balyasnikova, Ph.D. - Professor of Neurological Surgery, Northwestern University - The Feinberg School of Medicine
▪️ William Donaldson, Ph.D. - CEO, Estrigenix Therapeutics, Inc.
▪️ Sander Houten, Ph.D. - Associate Professor, Icahn School of Medicine at Mount Sinai 
▪️ Martin Matzuk, M.D., Ph.D. - Director, Center for Drug Discovery and Chair, Department of Pathology & Immunology, Baylor College of Medicine
▪️ Ariella Shikanov, Ph.D. - Associate Professor of Biomedical Engineering, University of Michigan
▪️ Stephanie Stanford, Ph.D. - R&D Director, Knoubis Bio, Inc.
▪️ Christina Woo, Ph.D. - Morris Kahn Associate Professor of Chemistry and Chemical Biology, Harvard University
 
Learn more about the symposium and the how it is supporting the future of #biotech: www.science2startup.com
 
If you are interested to get involved, please email us at: info@science2startup.com

#Science2Startup is next week, and we’re excited to share more about each of the presenters.

Today’s Science2Startup presenter spotlight is Ariella Shikanov, Ph.D., Associate Professor of Biomedical Engineering at University of Michigan.

Shikanov’s presentation will focus on: “Restoring Natural Ovarian Endocrine Function for Pediatric Cancer Survivors”

Follow along for updates!

#Science2Startup is next week, and we’re excited to share more about each of the presenters.

Today’s Science2Startup presenter spotlight is Rivka Dikstein, Ph.D., Professor and Dean, Faculty of Biochemistry at Weizmann Institute of Science.

Dikstein’s presentation will focus on: “Spt5-Pol II Inhibitors as an Effective Therapeutic Approach for Huntington's Disease” 
Follow along for updates!

We are thrilled to welcome David R. Liu, Ph.D. to lead our fireside chat at this year’s #Science2Startup symposium in Cambridge, MA on April 10th. 
 
Liu is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard; Thomas Dudley Cabot Professor of the Natural Sciences & Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator. 
 
His major research interests include the engineering, evolution, and in vivo delivery of genome editing agents to study and treat genetic diseases; the evolution of novel therapeutic proteins using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic molecules using DNA-templated organic synthesis and DNA-encoded libraries.
 
As a renowned business leader, he has successfully launched, led and scaled companies and products in the #healthcare space.
 
Learn more about the event and the unique opportunity for entrepreneurs and researchers in the biotech space to meet, collaborate, and learn from one another: www.science2startup.com 
 
If you are interested to get involved, please email us at: info@science2startup.com

A big congratulations to Cody Finke, Ph.D. and the Brimstone team!

VC:OUP

Outward VC